Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
London pre-open: Stocks seen muted ahead of mini-budget
(Sharecast News) - London stocks were set for a muted open on Friday as investors eyed the mini-budget. The FTSE 100 was called to open unchanged at 7,159.
CMC Markets analyst Michael Hewson said: "Today's European open looks set to be a positive one as we come to the end of what looks set to be another negative week for markets in Europe."
As far as the mini-budget is concerned, Hewson said: "At the very least we'll see the national insurance rise that was so heavily criticised in April reversed, from November, while the corporation tax rise that was due to take effect next year will be cancelled.
"Other trial balloons this week have been cuts to stamp duty and the removal of the cap on bankers' bonuses, which suggest a focus in areas that probably aren't a high priority at this moment in time.
"Rather than focussing on stamp duty, it would be more helpful in the move towards renewables to encourage or mandate the installation of solar panels on all new house building projects, as one example, in order to help reduce carbon footprints, and improve the energy efficiency of the housing stock.
"What would be more helpful would be an overhaul of the business rates system, as well as simplifying the way online businesses pay tax, relative to their bricks and mortar peers. While this hasn't been leaked it doesn't mean that the Chancellor might not be forthcoming when it comes to what he has up his sleeve later today."
Ahead of the budget, investors will be mulling the latest survey from GfK, which showed that UK consumer confidence has tumbled to fresh lows as the cost-of-living crisis continues to weigh heavily.
The GfK Consumer Confidence Index fell five points in September to a record low of -49, the worst overall index score since records began in 1974.
Within that, the personal financial situation index for the next 12 months, which measures consumers' expectations, slid nine points to -40, while the general economic situation index for the next year lost eight points to -68.
The major purchase index, which indicates how likely consumers are to spend on big ticket items, was unchanged at -38.
Joe Staton, client strategy director at GfK, said the falls seen on the forwarding-looking indices were "especially worrying".
He continued: "These numbers are where many forecasters look for signs of economic optimism among consumers, and the results deliver very bad news in that respect.
"Consumers are buckling under the pressure of the UK's growing cost-of-living crisis, driven by rapidly rising food prices, domestic fuel bills and mortgage payments. They are asking themselves when and how they situation will improve."
In corporate news, engineering company Smiths Group said full-year organic revenues and pre-tax profits had grown ahead of expectations amid "high demand" across the majority of its end markets.
Smiths stated that organic revenues had increased 3.8% to £2.56bn, marking a fifth consecutive quarter of growth, while pre-tax profits surged 263.2% to £1.03bn.
Drugmaker AstraZeneca said that Ultomiris, its long-acting C5 inhibitor, had received EU approval to be used in the treatment of adult patients with generalised myasthenia gravis, a rare autoimmune neuromuscular disease.
AstraZeneca stated that the European Commission's decision, which comes on the back of results from its CHAMPION-MG Phase III trial, marked the first and only approval for a long-acting C5 complement inhibitor for the treatment of gMG in Europe.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.